![Sandra Downes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sandra Downes
Corporate Officer/Principal en The University of Manchester .
Cargos activos de Sandra Downes
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
The University of Manchester | Corporate Officer/Principal | 20/11/2009 | - |
Historial de carrera de Sandra Downes
Antiguos cargos conocidos de Sandra Downes.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20/11/2009 | 18/01/2011 |
Estadísticas
Internacional
Reino Unido | 2 |
Israel | 2 |
Operativa
Corporate Officer/Principal | 2 |
Sectorial
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
- Bolsa de valores
- Insiders
- Sandra Downes
- Experiencia